Previous 10 | Next 10 |
REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK &am...
2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...
2023-03-07 16:15:00 ET Healthcare stocks have rebounded to a degree since the start of 2023, but a wide swath of these equities are still trading well below their all-time highs following the 2022 bear market. A small handful of healthcare stocks, however, have managed to defy this down...
2023-03-06 14:27:54 ET Summary Reata Pharmaceuticals, Inc. recently enjoyed a robust rally due to the FDA approval of its lead drug, omaveloxolone (Oma) for Friedreich's ataxia. The label for omaveloxolone is clean without a boxed warning or any other contraindications. As it'...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced tha...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Reata Pharmaceuticals, Inc. (NasdaqGM: RETA). In December 2021, the U.S. Food and Drug Admini...
Shares of the rare disease specialist Reata Pharmaceuticals (NASDAQ: RETA) jumped by 94.1% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence . The big gain after Reata announced that the Food and Drug Administra...
Weighed down by more hawkish comments from Federal Reserve officials, the Nasdaq and S&P 500 posted another day of modest declines on Wednesday. Meanwhile, the Dow managed to eke out a thin gain. Novavax ( NASDAQ: NVAX ) was among the standouts to the downside. Shares lost more th...
Reata Pharmaceuticals ( NASDAQ: RETA ) shares gained ~191% on Wednesday to reach the highest level since Dec. 2021 as Wall Street welcomed the FDA approval of its rare disease therapy omaveloxolone for neuromuscular disease Friedreich's ataxia. Nearly ~11.2M Reata ( RETA )...
Reata Pharmaceuticals is up 183% in Wednesday afternoon terading after the US FDA on Tuesday approved the company's Friedreich's ataxia drug Skyclarys (omaveloxolone). The treatment comes with an annual list price of $330K. Skyclarys is the first drug approved for the rare mo...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...